Paper41345397
Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion.
Iyengar NM and 9 others. NPJ Breast Cancer, 2025. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion. Papers, record 41345397. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41345397
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P30 CA008748 | NCI NIH HHS | United States | P30CA008748 | PubMed |
Source NIH RePORTER
References56
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36187122 | Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of randomized controlled trials. | Front Endocrinol (Lausanne) | 2022 | https://conductscience.org/library/papers/36187122 | PubMed |
| 2 | 26240704 | Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review. | World J Diabetes | 2015 | https://conductscience.org/library/papers/26240704 | PubMed |
| 3 | 34964875 | 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. | Diabetes Care | 2022 | https://conductscience.org/library/papers/34964875 | PubMed |
| 4 | 38478799 | Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/38478799 | PubMed |
| 5 | 25057302 | The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. | Ther Adv Med Oncol | 2014 | https://conductscience.org/library/papers/25057302 | PubMed |
| 6 | 34916492 | Targeting PI3K/Akt signal transduction for cancer therapy. | Signal Transduct Target Ther | 2021 | https://conductscience.org/library/papers/34916492 | PubMed |
| 7 | 31629292 | Gastrointestinal tract metastasis presenting as intussusception in invasive lobular carcinoma of the breast: A case report. | Int J Surg Case Rep | 2019 | https://conductscience.org/library/papers/31629292 | PubMed |
| 8 | 38297009 | Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique. | NPJ Breast Cancer | 2024 | https://conductscience.org/library/papers/38297009 | PubMed |
| 9 | 24197877 | Detection of intestinal protozoa in the clinical laboratory. | J Clin Microbiol | 2014 | https://conductscience.org/library/papers/24197877 | PubMed |
| 10 | 33719380 | Topical Corticosteroids: Choice and Application. | Am Fam Physician | 2021 | https://conductscience.org/library/papers/33719380 | PubMed |
| 11 | 31091374 | Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31091374 | PubMed |
| 12 | 34067630 | The PI3K/Akt Pathway: Emerging Roles in Skin Homeostasis and a Group of Non-Malignant Skin Disorders. | Cells | 2021 | https://conductscience.org/library/papers/34067630 | PubMed |
| 13 | 24611020 | Akt/PKB activation and insulin signaling: a novel insulin signaling pathway in the treatment of type 2 diabetes. | Diabetes Metab Syndr Obes | 2014 | https://conductscience.org/library/papers/24611020 | PubMed |
| 14 | 31626273 | Management of toxicity to isoform α-specific PI3K inhibitors. | Ann Oncol | 2019 | https://conductscience.org/library/papers/31626273 | PubMed |
| 15 | 30649751 | Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology. | Drug Saf | 2019 | https://conductscience.org/library/papers/30649751 | PubMed |
| 16 | 32613539 | Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer. | Breast Cancer Res Treat | 2020 | https://conductscience.org/library/papers/32613539 | PubMed |
| 17 | 38812089 | The PI3K/Akt signaling axis and type 2 diabetes mellitus (T2DM): From mechanistic insights into possible therapeutic targets. | Cell Biol Int | 2024 | https://conductscience.org/library/papers/38812089 | PubMed |
| 18 | 35372075 | Systemic Deficiency of PTEN Accelerates Breast Cancer Growth and Metastasis. | Front Oncol | 2022 | https://conductscience.org/library/papers/35372075 | PubMed |
| 19 | 39241495 | Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study. | ESMO Open | 2024 | https://conductscience.org/library/papers/39241495 | PubMed |
| 20 | 39690017 | Acute hyperglycemic hyperosmolar syndrome associated with capivasertib, a new, oral targeted therapy for advanced breast cancer. | Am J Emerg Med | 2025 | https://conductscience.org/library/papers/39690017 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42865609 | Capivasertib-Associated Diabetic Ketoacidosis With Concurrent Myocardial Injury in a Patient With Pre-Existing Coronary Artery Disease. | Case Rep Endocrinol | 2026 | https://conductscience.org/library/papers/42865609 | PubMed |
| 42792909 | AKT Inhibitor Capivasertib as a Target for Osimertinib Combination Therapy in Lung Adenocarcinoma with EGFR Mutation. | Genes (Basel) | 2026 | https://conductscience.org/library/papers/42792909 | PubMed |
| 42443498 | Transcription factor targeting strategies in cancer: mechanisms, challenges and cutting-edge progress. | Acta Pharmacol Sin | 2026 | https://conductscience.org/library/papers/42443498 | PubMed |
| 42266036 | Navigating first- and second-line treatment options in hormone receptor-positive HER2-negative advanced breast cancer. | Oncologist | 2026 | https://conductscience.org/library/papers/42266036 | PubMed |
| 42194764 | Capivasertib as a Therapeutic Agent for Breast Cancer: Targeting AKT to Overcome Endocrine Resistance. | J Clin Med | 2026 | https://conductscience.org/library/papers/42194764 | PubMed |
| 42041716 | Preclinical Rationale, Clinical Efficacy, and Safety of the Selective AKT Kinase Inhibitor Capivasertib in Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Carcinoma: A Practical Narrative Review. | Curr Oncol | 2026 | https://conductscience.org/library/papers/42041716 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| NR4A1 | 3164 | PubTator's text mining | https://conductscience.org/library/genes/3164 | NCBI Gene |
| PIK3CA | 5290 | PubTator's text mining | https://conductscience.org/library/genes/5290 | NCBI Gene |
| PTEN | 5728 | PubTator's text mining | https://conductscience.org/library/genes/5728 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41345397
GET https://conductscience.org/api/papers/v1/41345397/references?page=2